(Q39178281)

9 September 2017

title

C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma (English)

1 reference

9 September 2017

1 reference

Futoshi Kawamata

1

1 reference

9 September 2017

Shigenori Homma

2

1 reference

9 September 2017

Hirofumi Kamachi

3

1 reference

9 September 2017

Takahiro Einama

4

1 reference

9 September 2017

Yasutaka Kato

5

1 reference

9 September 2017

Masumi Tsuda

6

1 reference

9 September 2017

Shinya Tanaka

7

1 reference

9 September 2017

Masahiro Maeda

8

1 reference

9 September 2017

Kazunori Kajino

9

1 reference

9 September 2017

Okio Hino

10

1 reference

9 September 2017

Norihiko Takahashi

11

1 reference

9 September 2017

Toshiya Kamiyama

12

1 reference

9 September 2017

Hiroshi Nishihara

13

1 reference

9 September 2017

Akinobu Taketomi

14

1 reference

9 September 2017

Satoru Todo

15

1 reference

9 September 2017

publication date

20 March 2013

1 reference

Journal of Gastroenterology

9 September 2017

published in

1 reference

9 September 2017

volume

49

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

81-92

1 reference

9 September 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Prediction of prognosis is not improved by the seventh and latest edition of the TNM classification for colorectal cancer in a single-center collective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Localization of mesothelin in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Value of mesothelin immunostaining in the diagnosis of mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Inhibition of mesothelin as a novel strategy for targeting cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Forced expression of deltaN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Identification of proteins associating with glycosylphosphatidylinositol- anchored T-cadherin on the surface of vascular endothelial cells: role for Grp78/BiP in T-cadherin-dependent cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0773-6

Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan

21 January 2018

1 reference

12 December 2020

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients

1 reference

12 December 2020

The relationship of survival to staging and grading of colorectal carcinoma: A prospective study of 503 cases

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

Application of Mesothelin Immunostaining in Tumor Diagnosis

1 reference

12 December 2020

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

1 reference

12 December 2020

Visinin‐like protein‐1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients

1 reference

12 December 2020

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

1 reference

12 December 2020

Integrin-linked kinase is an essential mediator for T-cadherin-dependent signaling via Akt and GSK3beta in endothelial cells

1 reference

12 December 2020

Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial

1 reference

12 December 2020

Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma

1 reference

12 December 2020

Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

1 reference

12 December 2020

Suppression of cell death by the secretory form of N-terminal ERC/mesothelin.

1 reference

12 December 2020

10.1007/S00535-013-0773-6

Identifiers

DOI

1 reference

9 September 2017

1 reference